15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Cue Biopharma, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $4.00 to $4.00, so the covering firms are broadly aligned. The average target of $4.00 sits 88% below the current $32.72. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.91 next quarter toward $-9.45 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Moderate Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Cue Biopharma.
As of Jul, 1 of 1 firms rate CUE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CUE EPS & revenue forecast
EPS · NEXT QUARTER
$-1.91
Range $-1.91 – $-1.91 · 1 analysts · -9% YoY
Next period, 1 analysts expect Cue Biopharma to earn $-1.91 a share (range $-1.91 – $-1.91), versus $-2.10 a year earlier. Full-year consensus is $-6.64, growing to $-9.45 the year after.
REVENUE · NEXT QUARTER
$2.1M
Range $2.1M – $2.1M · 1 analysts · -2% YoY
Revenue is expected to reach $2.1M (range $2.1M – $2.1M), -2.3% year-over-year. Full-year consensus is $12.8M, rising to $1.0M next year.
Top analysts covering Cue Biopharma
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CUE.
#1
Reni J. Benjamin
JMP Securities · Rank #290
Buy
$2.00-93.9% to target
Overall win rate
33%
+ Follow
#2
DP
Dev Prasad
Lucid Capital
Buy
$4.00-87.8% to target
Coverage
—
+ Follow
#3
DP
Dev Prasad
LUCID CAPITAL MARKETS
Buy
$4.00-87.8% to target
Coverage
—
+ Follow
#4
SW
Stephen Willey
Stifel
Buy
$4.00-87.8% to target
Coverage
—
+ Follow
CUE stock forecast FAQ
What is CUE's average 12-month price target?+
The 1 analysts with a live target average $4.00 for Cue Biopharma over the next 12 months, ranging from a $4.00 high to a $4.00 low.
Is CUE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover CUE?+
1 analysts have an active rating on Cue Biopharma, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering CUE?+
Among analysts who currently cover CUE, Reni J. Benjamin of JMP Securities has the strongest overall Quantellect track record (Rank #290). Their current call is Buy with a $2.00 target.
What is Cue Biopharma's projected EPS for next quarter?+
The consensus estimate is $-1.91 per share (range $-1.91 – $-1.91) across 1 analysts. Full-year EPS is projected at $-6.64, rising to $-9.45 the following year.
How much revenue is Cue Biopharma expected to report next quarter?+
Consensus revenue is $2.1M (range $2.1M – $2.1M). Full-year revenue is projected at $12.8M, growing to $1.0M next year.
Have analysts been upgrading or downgrading CUE lately?+
As of Jul, 1 of 1 firms rate CUE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CUE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
